News Update

A Historic Day for Duchenne

PPMD President Pat Furlong reflects on today's Advisory Committee meeting for BioMarin.
November 24, 2015 | Learn more 

News Update

November 24: FDA Advisory Committee Meeting - Live Webcast Information

November 24th is a historic day for the Duchenne community as we enter into our first Advisory Committee Meeting with the FDA. Make sure to watch a live stream of the Ad Comm, or follow @ParentProjectMD on Twitter, using the hashtag ‪#‎DuchenneApprovals‬ for regular live updates.
November 23, 2015 | Learn more 

News Update

The Big Day is Almost Here!

Here’s the latest update on next week’s Ad Comm including logistical details for those attending in person, as well as how to watch a live stream from home. If you are attending, PPMD has worked closely with the FDA to make sure people needing extra assistance are comfortable throughout the day.
November 18, 2015 | Learn more 

News Update

FDA Advisory Committee Scenarios

Visit our blog to read more about what we have learned about the FDA Advisory Committee process and watch our webinar recording.
November 17, 2015 | Learn more 

News Update - eNews

End Duchenne eNews: Tackling Duchenne from Every Angle

Catch up on the latest research and community updates in this month's End Duchenne eNews.
November 16, 2015 | Learn more 

News Update

Webinar Recording: Understanding Myostatin Inhibition

Watch our webinar recording to learn more about the importance of myostatin inhibition research. Sponsored by educational partners Bristol-Myers Squibb and Pfizer, this webinar helped to put context and clarity around this treatment pathway so families have a better understanding as they see clinical trials in this area.
November 13, 2015 | Learn more 

News Update

PPMD Supports Advancing Targeted Therapies for Rare Diseases Act of 2015 (S. 2030)

For over a year, PPMD has been working with congressional champions and industry partners to help lead an effort to streamlining the regulatory pathways and review processes for targeted therapeutics (which would include such things as 'follow on exons') by clarifying the FDA’s existing authority to leverage data previously used in the approval of a targeted product when approving a new therapy.
November 12, 2015 | Learn more 

News Update - Action Alert

Webinar Recording: Decode Duchenne Genetic Testing Program

Watch our webinar recording to learn how the Decode Duchenne program works, who can apply, and why genetic testing is so important for you and your loved ones.
November 5, 2015 | Learn more 

News Update - Action Alert

Help Us Protect Your Wheelchair Technology!

The Centers for Medicare and Medicaid Services (CMS) has announced that it will apply Medicare competitive bid program pricing to Complex Rehab wheelchair accessories effective January 1, 2016; an action that will likely reduce access to wheelchair features many of our families depend on.
November 3, 2015 | Act now to prevent this action 

News Update

A Paradigm Shift in Drug Discovery

The Critical Path Hill Briefing that was just held demonstrated the importance of moving from “if and when [scientists and companies] are willing to share data” to an “institutionalized sharing of data.”
October 27, 2015 | Learn more 

News Update

PPMD Submits Results of Patient-Centered Benefit-Risk Assessment Study in Duchenne & Becker to FDA

PPMD is pleased to announce that late yesterday we submitted the results of our most recent patient-centered benefit-risk assessment study to the FDA. Based on this study, we are hopeful the FDA will have a better understanding of preferences of Duchenne patients and caregivers in regards to a specific pulmonary therapeutic target.
October 22, 2015 | Learn more 

News Update

How You Can Participate in the Upcoming FDA Advisory Committee Meetings

With the recent announcement of Advisory Committee (Ad Comm) dates for both BioMarin and Sarepta, families in our community are eager to be engaged and understandably have many questions. Here is a quick guide to what information has been confirmed and how you can participate.
October 20, 2015 | Learn more 

News Update

Ad Comms Update: Group Letter Submitted to FDA

PPMD is proud to help author and share the attached letter to Dr. Janet Woodcock at the FDA. Along with CDMD at UCLA, the Duchenne Alliance, and The Race to Yes, PPMD is asking Dr. Woodcock to consider moving Sarepta’s Advisory Committee date to the same week in November as BioMarin’s.
October 19, 2015 | Learn more 

News Update

Ad Comms Update: An Overwhelming Day

We all have many questions about what the January Ad Comm date for Sarepta, after the PDUFA date for BioMarin may mean. And PPMD is working with our regulatory experts to seek those answers and to understand how we can continue to work together as a community to ensure that both products are offered regulatory pathways to success so that patients ultimately may have access to either product, if approved.
October 14, 2015 | Learn more 

News Update

PPMD’s PRO Project: Adding more tools to help with upcoming clinical trials in Duchenne

Patient-report outcomes (PROs) are an important tool that allow patients and families to provide structured input about their own experiences and can be used in clinical trials and other research to help measure meaningful differences over time. Our community needs more meaningful PROs so that we have as many tools in our toolbox to help with upcoming clinical trials. That’s why PPMD wants to take a deeper dive into what is most important to you --  what would you value and expect as a result of a new therapeutic?
October 13, 2015 | Learn more 

News Update

PPMD Urges Senate to Move Forward on #Cures2015 Innovation for Healthier Americans Bill

PPMD continues to urge Members of Congress to support the Patient-Focused Impact Assessment Act (PFIA) as part of the Innovation for Healthier Americans bill. Please help us ensure that all Senators are aware of PFIA by reaching out today.
October 9, 2015 | Learn more 

Connect with PPMD
Facebook YouTube Twitter

Quick Links
How We Help

Our family-centered approach is at the heart of everything we do. Learn more.

Quick Links

Fund Research

More Links

PPMD Sites

new amazon banner